Molecular imaging developer Gamma Medica plans to conduct clinical studies of its LumaGem molecular breast imaging (MBI) system and compare outcomes with competing breast imaging modalities.
The firm has raised capital for comparative effectiveness studies at multiple sites that would compare MBI with other breast imaging modalities such as tomosynthesis and MRI.
Gamma Medica has also established a new scientific team to support the further development of LumaGem. This multidisciplinary team, led by Haris Kudrolli, PhD, of Boston University, will explore various approaches to decrease MBI procedure time and improve image quality, the company said.
